Declaration of Voting Results & Voting Rights Announcements • Dec 7, 2017
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Lyon, France, December 7th, 2017- 6pm CET - Pursuant to the provisions of article L. 233- 8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of November 30th, 2017.
| Month | Date | Total number of outstanding shares |
Total number of theoretical voting rights (1) |
Total number of exercisable voting rights (2) |
|---|---|---|---|---|
| November | 11/30/2017 | 6 861 763 | 9 541 936 | 9 534 020 |
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's portfolio of injectable treatments for diabetes, featuring five clinicalstage products and five preclinical products, is among the largest and most differentiated of the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Additionally, an aqueous formulation of human glucagon (BioChaperone Human Glucagon) has recently entered clinical testing. Adocia is also developing two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
Adocia aims to deliver "Innovative medicine for everyone, everywhere." To learn more about Adocia, please visit us at www.adocia.com
| Adocia | Adocia Press Relations | Adocia Investor Relations |
|---|---|---|
| Gérard Soula | Europe | USA |
| Chairman and CEO | MC Services AG | The Ruth Group |
| [email protected] | Raimund Gabriel | Tram Bui |
| Ph. : +33 4 72 610 610 | [email protected] | [email protected] |
| Ph. : +49 89 210 228 0 | Ph.: +1 646 536 7035 | |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.